Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). "We are pleased to have submitted the final module of the PMA application," said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. "This submission is a key fundamental milestone for Evolus and we look forward to our continued collaboration with the Agency in the upcoming thorough review process." Evolus anticipates that the FDA's review process will adhere to the standard timeline, with approval expected in the second half of 2025. The submission underscores Evolus' commitment to bringing the dermal filler products to market and its readiness to meet regulatory requirements. The PMA application includes results from the U.S. pivotal study, which evaluated the safety and effectiveness of the products
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Evolus, Inc. (NASDAQ: EOLS) had its price target raised by analysts at Barclays PLC from $16.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
- Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
EOLS
Earnings
- 7/31/24 - Miss
EOLS
Sec Filings
- 9/6/24 - Form 4
- 9/4/24 - Form 4
- 7/31/24 - Form 10-Q
- EOLS's page on the SEC website